GHRH Antagonists Exhibit Antioxidant Effects in Prostate Cancer Cells
Antioxidant activity of growth hormone-releasing hormone antagonists in LNCaP human prostate cancer line.
Background
Prostate cancer is a prevalent malignancy, and oxidative stress plays a significant role in its initiation and progression, contributing to DNA damage and cellular dysfunction. Growth hormone-releasing hormone (GHRH) antagonists are a class of compounds known for their anti-proliferative effects in various cancers, including prostate cancer. However, the exact mechanisms underlying their therapeutic benefits are still being elucidated, and there has been a specific knowledge gap regarding whether these antagonists possess direct antioxidant properties that could contribute to their anti-cancer activity.